Ubaldo Armato | Drug Delivery Systems | Innovative Research Award

Innovative Research Award

Ubaldo Armato
University of Verona, Italy

Ubaldo Armato
Affiliation University of Verona
Country Italy
Scopus ID 16502026200
Documents 179
Citations 3,838
h-index 34
Subject Area Drug Delivery Systems
Event International Top Pharmaceutical Awards

The Innovative Research Award recognizes scholarly excellence and sustained contributions to pharmaceutical and biomedical sciences. Ubaldo Armato of the University of Verona has established a notable academic profile through multidisciplinary investigations involving cellular biology, pathology, and drug delivery systems. His publication record and citation impact demonstrate consistent engagement with internationally recognized scientific research activities.[1]

Abstract

This article summarizes the academic achievements of Ubaldo Armato in relation to the Innovative Research Award. The assessment considers publication productivity, citation influence, and scientific engagement within pharmaceutical and biomedical research domains. Particular attention is given to contributions associated with drug delivery systems, pathology, and translational biomedical sciences. The review highlights measurable scholarly indicators and research dissemination activities documented through recognized academic databases.[1]

Keywords

Innovative Research Award, Ubaldo Armato, Drug Delivery Systems, Biomedical Sciences, Pharmaceutical Research, Scopus Author Profile, Citation Impact, Research Excellence.

Introduction

Academic awards provide recognition for scientific advancement and sustained scholarly engagement. Researchers working across pharmaceutical and biomedical disciplines contribute significantly to the understanding of disease mechanisms, therapeutic innovation, and translational medicine. Within this context, Ubaldo Armato’s scholarly record reflects an established commitment to research dissemination and interdisciplinary collaboration. His academic profile aligns with the objectives commonly associated with international scientific recognition programs.[2]

Research Profile

Ubaldo Armato is affiliated with the University of Verona and has contributed to numerous peer-reviewed publications indexed within international databases. His scholarly activities encompass cellular pathology, neurobiology, oncology, and pharmaceutical sciences. The documented publication count, citation metrics, and h-index collectively indicate long-term participation in impactful scientific research. These indicators are frequently utilized in evaluating academic productivity and research visibility.[1]

Research Contributions

Research contributions associated with Armato’s work include investigations into cellular responses, disease progression mechanisms, and biomedical applications relevant to therapeutic development. His studies have supported scientific understanding in areas connected to pharmaceutical innovation and biological systems analysis. Collaborative publications have further expanded the reach of these findings within international research communities. Such contributions continue to inform future studies and interdisciplinary inquiry.[3]

Publications

The research portfolio includes journal articles, collaborative studies, reviews, and biomedical investigations published through recognized academic channels. Publications have addressed molecular mechanisms, pathology, therapeutic approaches, and broader pharmaceutical applications. Citation activity associated with these works reflects continuing scholarly engagement and relevance within scientific literature. Multiple outputs have contributed to ongoing discussions in biomedical and pharmaceutical research communities.[1]

Research Impact

Research impact may be evaluated through citation frequency, interdisciplinary influence, and the continued use of published findings by subsequent investigators. With more than three thousand citations and a substantial h-index, Armato’s work demonstrates measurable visibility within academic literature. These metrics indicate that published studies have contributed to ongoing scientific dialogue and knowledge development. Research impact remains an important consideration in international award evaluations.[3]

Award Suitability

The Innovative Research Award emphasizes scholarly excellence, innovation, and meaningful contributions to scientific advancement. Based on publicly available academic indicators, publication records, and citation performance, Ubaldo Armato presents a profile consistent with the objectives of international research recognition initiatives. His multidisciplinary work and documented research productivity support consideration within competitive academic award frameworks. Evaluation remains subject to the criteria established by the awarding organization.[1]

Conclusion

Ubaldo Armato’s academic record reflects sustained participation in biomedical and pharmaceutical research. Publication activity, citation influence, and interdisciplinary engagement demonstrate a measurable contribution to scientific knowledge. These characteristics align with the broader objectives of recognizing impactful scholarship and innovation. The Innovative Research Award provides a framework through which such achievements may be formally acknowledged within the international scientific community.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ubaldo Armato, Author ID 16502026200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=16502026200
  2. Jiang, L., Yang, S., Zhang, F., … De Santis, D., & Li, H. Cell-Free Adipose Liquid Extract Combined with Vascularized Lymph Node Transfer for Treating Lymphedema: Implications for Human Therapy.
    https://pubmed.ncbi.nlm.nih.gov/42479418/
  3. Chiarini, A.M., Armato, U., Gui, L., … Chang, S., & Dal Prà, I. Early divergent modulation of NLRP2′s and NLRP3′s inflammasome sensors vs. AIM2′s one by signals from Aβ·Calcium-sensing receptor complexes in human astrocytes.
    https://pubmed.ncbi.nlm.nih.gov/39426463/

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile 

Education 

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience 

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards 

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus 

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Oliwia Kordyl | Drug Delivery Systems | Best Research Article Award

Oliwia Kordyl | Drug Delivery Systems | Best Research Article Award

Ms. Oliwia Kordyl, Poznan Univeristy of Medical Sciences, Poland

Ms. Oliwia Kordyl (b. June 9, 1997) is a dedicated PhD student at Poznan University of Medical Sciences, specializing in 3D printed microneedles for targeted drug delivery. With a background in biotechnology from Adam Mickiewicz University, her work spans molecular biology, pharmaceutical technology, and reproductive genetics. Oliwia has held roles as a lab manager, molecular biologist, and biotechnologist, contributing to innovative projects and scientific conferences. She is skilled in advanced lab techniques and passionate about travel, fitness, and continuous learning.

Publication Profile

orcid

Education

Ms. Oliwia Kordyl is currently pursuing her Ph.D. (Nov 2023–Present) at the Poznan University of Medical Sciences in Poland, focusing on 3D printed microneedles for voriconazole delivery in treating local skin infections. Her research involves optimizing microneedle manufacturing, assessing physicochemical and pharmaceutical properties in vitro, and evaluating drug permeation ex vivo and microbiological effectiveness 🧪🧬. She earned her M.Sc. and B.Sc. in biotechnology from Adam Mickiewicz University (2016–2021), where she explored DNA methylation in oligozoospermia and gene expression in spermatogenesis 🧫. Her academic journey began at K.K. Baczyński Secondary School, specializing in biology, physics, and chemistry 🔬📚.

Experience

Ms. Oliwia Kordyl completed a valuable internship at Novazym Polska in Poznań from July to August 2019. During her time at this renowned biotechnology company, she gained hands-on experience in laboratory techniques and deepened her understanding of industrial biotechnology practices 🔬💼. The internship provided her with practical insights into the daily operations of a biotech firm and allowed her to apply her academic knowledge in a real-world setting 🧪📊. This experience not only enhanced her technical skills but also strengthened her passion for research and innovation in the field of biotechnology, laying a strong foundation for her future scientific endeavors 🚀.

Awards

🏆 Ms. Oliwia Kordyl has actively contributed to the scientific community through speeches and posters at esteemed conferences. She presented on sperm DNA methylation at the 21st Andrology Day (2019) 🧬 and the 21st European Testis Workshop (2021) in Barcelona. Her posters featured at ESHRE 2020, the European Human Genetics Conference (2021), and the 6th Polish Congress of Genetics (2022) showcased her expertise in epigenetics and sperm chromatin structure 🧫📊. In 2023, she co-authored a poster on microneedles for transdermal drug delivery at PolGerSym10 💉. Oliwia also co-authored a publication in the International Journal of Molecular Sciences (2022) 📄📚.

Research Focus

Ms. Oliwia Kordyl’s research focuses on the development of innovative drug delivery systems, particularly microneedle-based technologies for transdermal applications. Her work combines 3D printing, pharmaceutical coatings, and hydrogel systems to enhance the treatment of bacterial and fungal skin infections. She also explores photodynamic therapy and nanotechnology for targeted drug release. Her interdisciplinary approach bridges materials science, biomedical engineering, and pharmaceutics. Additionally, her research extends to epigenetic analysis in human sperm, highlighting her interest in reproductive biology. Her work is at the frontier of personalized medicine, non-invasive therapies, and advanced pharmaceutical technologies.

Publication Top Notes

Optimization of LCD-Based 3D Printing for the Development of Clotrimazole-Coated Microneedle Systems

Microneedle-based arrays – Breakthrough strategy for the treatment of bacterial and fungal skin infections

Microneedle System Coated with Hydrogels Containing Protoporphyrin IX for Potential Application in Pharmaceutical Technology

Global 5mC and 5hmC DNA Levels in Human Sperm Subpopulations with Differentially Protaminated Chromatin in Normo- and Oligoasthenozoospermic Males